OMH Osmetech

RNS Number:3701H
Osmetech PLC
16 March 2000

                      Osmetech plc
              ("Osmetech" or "the Company")

  Successful Initial Bacterial Vaginosis Clinical Study
                            
The  Board  of  Osmetech is pleased to  announce  that  a
recent clinical study of 100 patients at South Manchester
Hospital   University  Trust  indicates  that  Osmetech's
electronic  nose  can  detect  Bacterial  Vaginosis  (BV)
reliably and rapidly.  This represents a new and exciting
application  that  will broaden the  existing  healthcare
portfolio for Osmetech's electronic nose technology.

Dr. Wang Chong, Chief Executive, said

"Our device has the potential to improve medical practice
significantly. BV is currently diagnosed by  a  composite
of  three  out of four criteria, a relatively  subjective
method.   Our device will enable physicians  to  make  an
objective diagnosis rapidly.

"BV  is the commonest cause of abnormal vaginal discharge
in  the  western  world.  BV has  a  prevalence  rate  of
between    10%-20%   and   accounts   for   10    million
gynaecological visits in the US each year and is  a  risk
factor  for  a  host  of  obstetric,  gynaecological  and
neonatal complications, including miscarriage and preterm
birth.

"We  are confirming our initial study results by a larger
clinical  study  of up to 1000 patients  at  St  George's
Hospital,  London, where we will be working with  one  of
the  world's  leading physicians on the  subject  of  BV.
Assuming that this larger study is successful, we will be
seeking an FDA approval."
   
For further information, please contact:

Osmetech  plc                              01270  216 444
James White

Square  Mile  Communications                0207 601 1000
Nick Oborne/ Mike Wort


END
MSCEAXDSFSLEEFE

Osmetech (LSE:OMH)
Historical Stock Chart
From Jun 2024 to Jul 2024

Osmetech (LSE:OMH)
Historical Stock Chart
From Jul 2023 to Jul 2024